In particular, two of these ZFGs, ESR1, and ZNF132, showed a significantly higher diagnostic capability than SEPT9, suggesting that they might be promising biomarkers for CRC diagnosis, especially for KRAS mutated patients. This evidence concerns the gene ZNF132 and colorectal carcinoma.